MedTrace Logo

Minimal Effective Concentration (EC90) of Ropivacaine

NCT03688269 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2020-12-21

No results posted yet for this study

Summary

Prospective up and down sequential evaluation of the minimal effective concentration of perineural ropivacaine for 90% success in axillary brachial plexus block with the injection of intravenous dexamethasone or saline placebo during regional anesthesia performance

Conditions

  • Anesthesia, Conduction
  • Ropivacaine
  • Dexamethasone
  • Axillary Brachial Plexus Block

Interventions

DRUG

Intravenous dexamethasone

Intravenous injection of 8mg/2ml dexamethasone

DRUG

Intravenous saline

Intravenous injection of 2ml Saline 0.9%

DRUG

Perineural ropivacaine

Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Principal Investigators

  • Francis BERTHIER · Centre Hospitalier Universitaire de Besancon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-05
Primary Completion
2019-11-04
Completion
2020-05-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688269 on ClinicalTrials.gov